P16基因甲基化与淋巴细胞-浆细胞肿瘤的发生发展  

Methylation of P16 Gene with Pathogenesis of Lymphocytic and Plasmacytic Malignancies——Review

作　　者：王鸣明[1] 

机构地区：[1]上海第九人民医院血液科,上海血液研究所上海200011

出　　处：《中国实验血液学杂志》2007年第5期1126-1129,共4页Journal of Experimental Hematology

摘　　要：基因启动子区CpG岛甲基化常导致基因沉默。P16基因是一定位于9p21的多种肿瘤抑制基因,通过pl6INK4A-cyclinD1-PRb通路维持机体细胞的有序增殖。P16基因甲基化在淋巴瘤、急性淋巴细胞性白血病、多发性骨髓瘤等多种淋巴细胞-浆细胞肿瘤中被检测到,并与疾病的发生、发展存在一定关系,应用甲基化抑制因子或砷剂去甲基化治疗,恢复基因功能可望成为血液恶性肿瘤治疗的一种新手段。本文就P16基因甲基化机制及P16基因甲基化与淋巴细胞-浆细胞肿瘤(淋巴瘤、急性和慢性淋巴细胞白血病、多发性骨髓病)的关系作一综述。Methylation of CpG islands in the promoters induces gene silencing. The multiple tumor suppressor gene P16, located at chromosome 9p21, regulating normal proliferation of cells with a functional unit constituting of pl6, cyclin D1 and pRb together. Methylation of P16 gene has been detected in several lymphocytic and plasmacytic malignancies such as lymphoma, acute lymphocytic leukemia and multiple myeloma and shows relationships with the pathogenesis of these diseases. Application of demethylation agents or arsenical to refresh the gene functions will be expected to be a new treatment for hemopoietic malignancies. In this article, methylation mechanism of P16 gene and relationship of P16 gene methylation with lymphocytic and plasmacytic malignancies, such as lymphoma, acute and chronic lymphocytic leukemia and multiple myeloma were reviewed.

关 键 词：P16基因 淋巴瘤 多发性骨髓瘤 甲基化 浆细胞肿瘤 

分 类 号：R733.1[医药卫生—肿瘤] R733.3[医药卫生—临床医学]